WO2003106689A1 - 光学活性α−メチルシステイン誘導体の製造方法 - Google Patents
光学活性α−メチルシステイン誘導体の製造方法 Download PDFInfo
- Publication number
- WO2003106689A1 WO2003106689A1 PCT/JP2003/007108 JP0307108W WO03106689A1 WO 2003106689 A1 WO2003106689 A1 WO 2003106689A1 JP 0307108 W JP0307108 W JP 0307108W WO 03106689 A1 WO03106689 A1 WO 03106689A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- salt
- formula
- methyl
- carbon atoms
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 153
- NZBONMFLYFGTAC-BYPYZUCNSA-N (2r)-2-amino-2-methyl-3-sulfanylpropanoic acid Chemical class SC[C@@](N)(C)C(O)=O NZBONMFLYFGTAC-BYPYZUCNSA-N 0.000 title claims abstract description 47
- 150000003839 salts Chemical class 0.000 claims abstract description 216
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 51
- 125000004434 sulfur atom Chemical group 0.000 claims abstract description 51
- 108091022884 dihydropyrimidinase Proteins 0.000 claims abstract description 31
- 102100036238 Dihydropyrimidinase Human genes 0.000 claims abstract description 26
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 188
- 239000002253 acid Substances 0.000 claims description 102
- 238000004519 manufacturing process Methods 0.000 claims description 101
- 238000006243 chemical reaction Methods 0.000 claims description 98
- 150000001875 compounds Chemical class 0.000 claims description 91
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 87
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 84
- 125000004432 carbon atom Chemical group C* 0.000 claims description 79
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 76
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 66
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 64
- 239000000243 solution Substances 0.000 claims description 61
- 239000002904 solvent Substances 0.000 claims description 56
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 54
- 125000001424 substituent group Chemical group 0.000 claims description 53
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 51
- 125000000217 alkyl group Chemical group 0.000 claims description 50
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 50
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 48
- 239000003960 organic solvent Substances 0.000 claims description 48
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 45
- -1 methyl-D-cystine derivative Chemical class 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 43
- 239000007864 aqueous solution Substances 0.000 claims description 42
- 238000002425 crystallisation Methods 0.000 claims description 41
- 238000010511 deprotection reaction Methods 0.000 claims description 34
- 238000006460 hydrolysis reaction Methods 0.000 claims description 33
- 229910052700 potassium Inorganic materials 0.000 claims description 31
- 239000011591 potassium Substances 0.000 claims description 31
- 239000013078 crystal Substances 0.000 claims description 29
- 230000007062 hydrolysis Effects 0.000 claims description 27
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 25
- 229910017604 nitric acid Inorganic materials 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 23
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 22
- 125000003118 aryl group Chemical group 0.000 claims description 22
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 21
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 21
- 238000007363 ring formation reaction Methods 0.000 claims description 20
- 239000003513 alkali Substances 0.000 claims description 19
- 150000001469 hydantoins Chemical class 0.000 claims description 19
- 229960001913 mecysteine Drugs 0.000 claims description 19
- 239000002585 base Substances 0.000 claims description 18
- 244000005700 microbiome Species 0.000 claims description 18
- 239000004215 Carbon black (E152) Substances 0.000 claims description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 17
- 229930195733 hydrocarbon Natural products 0.000 claims description 17
- 150000002430 hydrocarbons Chemical class 0.000 claims description 17
- 230000002829 reductive effect Effects 0.000 claims description 16
- 229960002433 cysteine Drugs 0.000 claims description 15
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 12
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims description 12
- 150000007513 acids Chemical class 0.000 claims description 12
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 12
- 230000008025 crystallization Effects 0.000 claims description 12
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 claims description 12
- NZBONMFLYFGTAC-SCSAIBSYSA-N (2s)-2-amino-2-methyl-3-sulfanylpropanoic acid Chemical compound SC[C@](N)(C)C(O)=O NZBONMFLYFGTAC-SCSAIBSYSA-N 0.000 claims description 11
- 239000000920 calcium hydroxide Substances 0.000 claims description 11
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 11
- 235000019441 ethanol Nutrition 0.000 claims description 11
- DVOOXRTYGGLORL-VKHMYHEASA-N (2r)-2-(methylamino)-3-sulfanylpropanoic acid Chemical compound CN[C@@H](CS)C(O)=O DVOOXRTYGGLORL-VKHMYHEASA-N 0.000 claims description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 10
- 235000018417 cysteine Nutrition 0.000 claims description 10
- 238000011282 treatment Methods 0.000 claims description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 9
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 9
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 claims description 9
- 239000000347 magnesium hydroxide Substances 0.000 claims description 9
- 229910001862 magnesium hydroxide Inorganic materials 0.000 claims description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 8
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 claims description 8
- 229910001863 barium hydroxide Inorganic materials 0.000 claims description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 7
- JBTWLSYIZRCDFO-UHFFFAOYSA-N ethyl methyl carbonate Chemical compound CCOC(=O)OC JBTWLSYIZRCDFO-UHFFFAOYSA-N 0.000 claims description 7
- 238000001704 evaporation Methods 0.000 claims description 7
- 230000008020 evaporation Effects 0.000 claims description 7
- 150000007530 organic bases Chemical class 0.000 claims description 7
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 6
- 241000589516 Pseudomonas Species 0.000 claims description 6
- 239000008096 xylene Substances 0.000 claims description 6
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 claims description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 5
- 241000589158 Agrobacterium Species 0.000 claims description 5
- 108010093096 Immobilized Enzymes Proteins 0.000 claims description 5
- 239000004201 L-cysteine Substances 0.000 claims description 5
- 239000005456 alcohol based solvent Substances 0.000 claims description 5
- 229910052783 alkali metal Inorganic materials 0.000 claims description 5
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000004210 ether based solvent Substances 0.000 claims description 5
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 claims description 5
- 229940091173 hydantoin Drugs 0.000 claims description 5
- 241000589159 Agrobacterium sp. Species 0.000 claims description 4
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 claims description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- XLJMAIOERFSOGZ-UHFFFAOYSA-N cyanic acid Chemical compound OC#N XLJMAIOERFSOGZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
- 239000012046 mixed solvent Substances 0.000 claims description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 4
- 230000003313 weakening effect Effects 0.000 claims description 4
- 241000589776 Pseudomonas putida Species 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 claims description 2
- 230000021235 carbamoylation Effects 0.000 claims description 2
- 229910000000 metal hydroxide Inorganic materials 0.000 claims description 2
- 150000004692 metal hydroxides Chemical class 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- IOVCWXUNBOPUCH-UHFFFAOYSA-N Nitrous acid Chemical compound ON=O IOVCWXUNBOPUCH-UHFFFAOYSA-N 0.000 claims 2
- 125000000732 arylene group Chemical group 0.000 claims 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- XUJNEKJLAYXESH-UWTATZPHSA-N D-Cysteine Chemical compound SC[C@@H](N)C(O)=O XUJNEKJLAYXESH-UWTATZPHSA-N 0.000 claims 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims 1
- VKEQBMCRQDSRET-UHFFFAOYSA-N Methylone Chemical compound CNC(C)C(=O)C1=CC=C2OCOC2=C1 VKEQBMCRQDSRET-UHFFFAOYSA-N 0.000 claims 1
- 235000002595 Solanum tuberosum Nutrition 0.000 claims 1
- 244000061456 Solanum tuberosum Species 0.000 claims 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 claims 1
- 229960001305 cysteine hydrochloride Drugs 0.000 claims 1
- 238000007872 degassing Methods 0.000 claims 1
- 229940035429 isobutyl alcohol Drugs 0.000 claims 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract description 9
- 239000003814 drug Substances 0.000 abstract description 5
- 125000003277 amino group Chemical group 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- IAIUJFALVAFCBI-YFKPBYRVSA-N (2r)-2-(carbamoylamino)-2-methyl-3-sulfanylpropanoic acid Chemical class SC[C@@](C)(C(O)=O)NC(N)=O IAIUJFALVAFCBI-YFKPBYRVSA-N 0.000 abstract description 2
- 239000000463 material Substances 0.000 abstract 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 34
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 30
- 108090000790 Enzymes Proteins 0.000 description 27
- 102000004190 Enzymes Human genes 0.000 description 27
- 239000012071 phase Substances 0.000 description 26
- 238000001514 detection method Methods 0.000 description 24
- 230000003287 optical effect Effects 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Natural products CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 23
- 239000000047 product Substances 0.000 description 21
- 238000001914 filtration Methods 0.000 description 19
- 235000011054 acetic acid Nutrition 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 238000004128 high performance liquid chromatography Methods 0.000 description 16
- 125000006239 protecting group Chemical group 0.000 description 15
- 238000003756 stirring Methods 0.000 description 14
- RHYBFKMFHLPQPH-UHFFFAOYSA-N N-methylhydantoin Chemical class CN1CC(=O)NC1=O RHYBFKMFHLPQPH-UHFFFAOYSA-N 0.000 description 13
- 238000005481 NMR spectroscopy Methods 0.000 description 12
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 12
- 230000009257 reactivity Effects 0.000 description 12
- 239000000758 substrate Substances 0.000 description 12
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 11
- 235000019796 monopotassium phosphate Nutrition 0.000 description 11
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 229910017053 inorganic salt Inorganic materials 0.000 description 10
- IDIDJDIHTAOVLG-VKHMYHEASA-N S-methylcysteine Chemical class CSC[C@H](N)C(O)=O IDIDJDIHTAOVLG-VKHMYHEASA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 150000003862 amino acid derivatives Chemical class 0.000 description 9
- 239000007810 chemical reaction solvent Substances 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- MAGCVRLGTQSVGF-WCCKRBBISA-N (2r)-2-amino-2-methyl-3-sulfanylpropanoic acid;hydrochloride Chemical compound Cl.SC[C@@](N)(C)C(O)=O MAGCVRLGTQSVGF-WCCKRBBISA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 230000014759 maintenance of location Effects 0.000 description 8
- 235000005956 Cosmos caudatus Nutrition 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 7
- 229940099596 manganese sulfate Drugs 0.000 description 7
- 239000011702 manganese sulphate Substances 0.000 description 7
- 235000007079 manganese sulphate Nutrition 0.000 description 7
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 description 7
- 239000002994 raw material Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical class CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 241001131785 Escherichia coli HB101 Species 0.000 description 6
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 6
- 229960003067 cystine Drugs 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 239000002002 slurry Substances 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 229940041514 candida albicans extract Drugs 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000006911 enzymatic reaction Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000008057 potassium phosphate buffer Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 230000035484 reaction time Effects 0.000 description 5
- 239000012138 yeast extract Substances 0.000 description 5
- LPLLVINFLBSFRP-UHFFFAOYSA-N 2-methylamino-1-phenylpropan-1-one Chemical compound CNC(C)C(=O)C1=CC=CC=C1 LPLLVINFLBSFRP-UHFFFAOYSA-N 0.000 description 4
- 241000132539 Cosmos Species 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 4
- 239000004158 L-cystine Substances 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 238000005903 acid hydrolysis reaction Methods 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000003957 anion exchange resin Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- NMJNPLIFGMSGNZ-MRVPVSSYSA-N (2s)-2-amino-3-tert-butylsulfanyl-2-methylpropanoic acid Chemical compound CC(C)(C)SC[C@@](C)(N)C(O)=O NMJNPLIFGMSGNZ-MRVPVSSYSA-N 0.000 description 3
- CLCLQDMQZNAPJH-UHFFFAOYSA-N 5-(tert-butylsulfanylmethyl)-5-methylimidazolidine-2,4-dione Chemical compound CC(C)(C)SCC1(C)NC(=O)NC1=O CLCLQDMQZNAPJH-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 3
- 241000589180 Rhizobium Species 0.000 description 3
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 230000018044 dehydration Effects 0.000 description 3
- 238000006297 dehydration reaction Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- GKKCIDNWFBPDBW-UHFFFAOYSA-M potassium cyanate Chemical compound [K]OC#N GKKCIDNWFBPDBW-UHFFFAOYSA-M 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 125000004149 thio group Chemical group *S* 0.000 description 3
- WBIZYAXYAGDQGK-ZZJOKYKRSA-N (2r)-2-amino-3-[[(2r)-2-amino-2-carboxyethyl]disulfanyl]butanoic acid Chemical compound OC(=O)[C@@H](N)C(C)SSC[C@H](N)C(O)=O WBIZYAXYAGDQGK-ZZJOKYKRSA-N 0.000 description 2
- NMJNPLIFGMSGNZ-QMMMGPOBSA-N (2r)-2-amino-3-tert-butylsulfanyl-2-methylpropanoic acid Chemical compound CC(C)(C)SC[C@](C)(N)C(O)=O NMJNPLIFGMSGNZ-QMMMGPOBSA-N 0.000 description 2
- FJJYHTVHBVXEEQ-UHFFFAOYSA-N 2,2-dimethylpropanal Chemical compound CC(C)(C)C=O FJJYHTVHBVXEEQ-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- 241000588698 Erwinia Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 235000013878 L-cysteine Nutrition 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 241001236817 Paecilomyces <Clavicipitaceae> Species 0.000 description 2
- 241000607720 Serratia Species 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 2
- 229940092714 benzenesulfonic acid Drugs 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 229960001701 chloroform Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 150000001944 cysteine derivatives Chemical class 0.000 description 2
- 238000006471 dimerization reaction Methods 0.000 description 2
- 229940023064 escherichia coli Drugs 0.000 description 2
- 239000003759 ester based solvent Substances 0.000 description 2
- 229940093499 ethyl acetate Drugs 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000003100 immobilizing effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 2
- 229940011051 isopropyl acetate Drugs 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 2
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 2
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229940017219 methyl propionate Drugs 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 150000002825 nitriles Chemical class 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000007142 ring opening reaction Methods 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 125000003944 tolyl group Chemical group 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- MAGCVRLGTQSVGF-PGMHMLKASA-N (2s)-2-amino-2-methyl-3-sulfanylpropanoic acid;hydrochloride Chemical compound Cl.SC[C@](N)(C)C(O)=O MAGCVRLGTQSVGF-PGMHMLKASA-N 0.000 description 1
- CDTWGCLFGYMRDD-HTQZYQBOSA-N (2s)-2-amino-3-[[(2s)-2-amino-2-carboxypropyl]disulfanyl]-2-methylpropanoic acid Chemical class OC(=O)[C@@](N)(C)CSSC[C@@](C)(N)C(O)=O CDTWGCLFGYMRDD-HTQZYQBOSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- YCICXFIRAMLYDV-UHFFFAOYSA-N 1-methylcyclooctan-1-ol Chemical compound CC1(O)CCCCCCC1 YCICXFIRAMLYDV-UHFFFAOYSA-N 0.000 description 1
- ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
- MFGOFGRYDNHJTA-UHFFFAOYSA-N 2-amino-1-(2-fluorophenyl)ethanol Chemical compound NCC(O)C1=CC=CC=C1F MFGOFGRYDNHJTA-UHFFFAOYSA-N 0.000 description 1
- SOCJGQJVCHQBPY-UHFFFAOYSA-N 2-amino-3-(2-methoxyphenyl)-2-methylpropanoic acid Chemical compound COC1=CC=CC=C1CC(C)(N)C(O)=O SOCJGQJVCHQBPY-UHFFFAOYSA-N 0.000 description 1
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
- BYDRTKVGBRTTIT-UHFFFAOYSA-N 2-methylprop-2-en-1-ol Chemical compound CC(=C)CO BYDRTKVGBRTTIT-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- YIROYDNZEPTFOL-UHFFFAOYSA-N 5,5-Dimethylhydantoin Chemical compound CC1(C)NC(=O)NC1=O YIROYDNZEPTFOL-UHFFFAOYSA-N 0.000 description 1
- LJMLJHMBQGSIQP-UHFFFAOYSA-N 5-(methylsulfanylmethyl)imidazolidine-2,4-dione Chemical compound CSCC1NC(=O)NC1=O LJMLJHMBQGSIQP-UHFFFAOYSA-N 0.000 description 1
- VMAQYKGITHDWKL-UHFFFAOYSA-N 5-methylimidazolidine-2,4-dione Chemical compound CC1NC(=O)NC1=O VMAQYKGITHDWKL-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000589220 Acetobacter Species 0.000 description 1
- 241000590020 Achromobacter Species 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000187844 Actinoplanes Species 0.000 description 1
- 241000607534 Aeromonas Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000588986 Alcaligenes Species 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- OJZQDHYBQKHIHX-UHFFFAOYSA-N C(C)(C)(C)SCC1C(NC(N1)=O)=O Chemical compound C(C)(C)(C)SCC1C(NC(N1)=O)=O OJZQDHYBQKHIHX-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 101000644537 Homo sapiens Sequestosome-1 Proteins 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001467578 Microbacterium Species 0.000 description 1
- 241001072332 Monia Species 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 150000007945 N-acyl ureas Chemical group 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 241000609816 Pantholops hodgsonii Species 0.000 description 1
- 241000228143 Penicillium Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589774 Pseudomonas sp. Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 102100020814 Sequestosome-1 Human genes 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- AZFNGPAYDKGCRB-XCPIVNJJSA-M [(1s,2s)-2-amino-1,2-diphenylethyl]-(4-methylphenyl)sulfonylazanide;chlororuthenium(1+);1-methyl-4-propan-2-ylbenzene Chemical compound [Ru+]Cl.CC(C)C1=CC=C(C)C=C1.C1=CC(C)=CC=C1S(=O)(=O)[N-][C@@H](C=1C=CC=CC=1)[C@@H](N)C1=CC=CC=C1 AZFNGPAYDKGCRB-XCPIVNJJSA-M 0.000 description 1
- ZMZINYUKVRMNTG-UHFFFAOYSA-N acetic acid;formic acid Chemical compound OC=O.CC(O)=O ZMZINYUKVRMNTG-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- JINBYESILADKFW-UHFFFAOYSA-N aminomalonic acid Chemical class OC(=O)C(N)C(O)=O JINBYESILADKFW-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000010533 azeotropic distillation Methods 0.000 description 1
- GJTDJAPHKDIQIQ-UHFFFAOYSA-L barium(2+);dinitrite Chemical compound [Ba+2].[O-]N=O.[O-]N=O GJTDJAPHKDIQIQ-UHFFFAOYSA-L 0.000 description 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- HUCVOHYBFXVBRW-UHFFFAOYSA-M caesium hydroxide Inorganic materials [OH-].[Cs+] HUCVOHYBFXVBRW-UHFFFAOYSA-M 0.000 description 1
- LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 1
- 229940052299 calcium chloride dihydrate Drugs 0.000 description 1
- 210000000692 cap cell Anatomy 0.000 description 1
- AJAFRMGZWFDZAS-UHFFFAOYSA-M cesium;nitrite Chemical compound [Cs+].[O-]N=O AJAFRMGZWFDZAS-UHFFFAOYSA-M 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- CVOQYKPWIVSMDC-UHFFFAOYSA-L dipotassium;butanedioate Chemical compound [K+].[K+].[O-]C(=O)CCC([O-])=O CVOQYKPWIVSMDC-UHFFFAOYSA-L 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- SLGWESQGEUXWJQ-UHFFFAOYSA-N formaldehyde;phenol Chemical compound O=C.OC1=CC=CC=C1 SLGWESQGEUXWJQ-UHFFFAOYSA-N 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 description 1
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 238000011031 large-scale manufacturing process Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 1
- AAJBNRZDTJPMTJ-UHFFFAOYSA-L magnesium;dinitrite Chemical compound [Mg+2].[O-]N=O.[O-]N=O AAJBNRZDTJPMTJ-UHFFFAOYSA-L 0.000 description 1
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- CNFDGXZLMLFIJV-UHFFFAOYSA-L manganese(II) chloride tetrahydrate Chemical compound O.O.O.O.[Cl-].[Cl-].[Mn+2] CNFDGXZLMLFIJV-UHFFFAOYSA-L 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- HLNRBHDRGMNBEG-UHFFFAOYSA-N nitrous acid Chemical compound ON=O.ON=O HLNRBHDRGMNBEG-UHFFFAOYSA-N 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 229920001568 phenolic resin Polymers 0.000 description 1
- RAFRTSDUWORDLA-UHFFFAOYSA-N phenyl 3-chloropropanoate Chemical compound ClCCC(=O)OC1=CC=CC=C1 RAFRTSDUWORDLA-UHFFFAOYSA-N 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920005990 polystyrene resin Polymers 0.000 description 1
- 239000004304 potassium nitrite Substances 0.000 description 1
- 235000010289 potassium nitrite Nutrition 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000001325 propanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 229940090181 propyl acetate Drugs 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- ZVCDLGYNFYZZOK-UHFFFAOYSA-M sodium cyanate Chemical compound [Na]OC#N ZVCDLGYNFYZZOK-UHFFFAOYSA-M 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 description 1
- JBJWASZNUJCEKT-UHFFFAOYSA-M sodium;hydroxide;hydrate Chemical compound O.[OH-].[Na+] JBJWASZNUJCEKT-UHFFFAOYSA-M 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000707 stereoselective effect Effects 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- JTNXQVCPQMQLHK-UHFFFAOYSA-N thioacetone Chemical class CC(C)=S JTNXQVCPQMQLHK-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- JOQGJRQKCIJIDB-UHFFFAOYSA-N tin;hydrochloride Chemical compound Cl.[Sn] JOQGJRQKCIJIDB-UHFFFAOYSA-N 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000012137 tryptone Substances 0.000 description 1
- 241001624918 unidentified bacterium Species 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/12—Methionine; Cysteine; Cystine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C319/00—Preparation of thiols, sulfides, hydropolysulfides or polysulfides
- C07C319/02—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols
- C07C319/06—Preparation of thiols, sulfides, hydropolysulfides or polysulfides of thiols from sulfides, hydropolysulfides or polysulfides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/04—Oxygen as only ring hetero atoms containing a five-membered hetero ring, e.g. griseofulvin, vitamin C
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/10—Nitrogen as only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P41/00—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture
- C12P41/006—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures
- C12P41/009—Processes using enzymes or microorganisms to separate optical isomers from a racemic mixture by reactions involving C-N bonds, e.g. nitriles, amides, hydantoins, carbamates, lactames, transamination reactions, or keto group formation from racemic mixtures by reactions involving hydantoins or carbamoylamino compounds
Definitions
- the present invention relates to a method for producing an optically active L-form or D-form Q; -men derivative or a salt thereof, which is useful as an intermediate for pharmaceuticals and the like.
- any of the methods has a problem to be solved as an industrial method for producing an optically active methyl cysteine derivative or a salt thereof.
- optically active methyl cysteine derivative obtained through the above-mentioned method can be appropriately deprotected, if necessary, to obtain optically active ⁇ -methyl cysteine or a salt thereof.
- a method for isolating and purifying the optically active monomethyl cysteine or a salt thereof obtained therefrom a method by crystallization is considered preferable.
- optically active a-methylcysteine or a salt thereof is crystallized and obtained as a crystal. Only a few examples of the isolation are described in WO 01/72702 and the like.
- These compounds are obtained by deprotecting a thiazolidine compound which is an optically active ⁇ -methylcysteine derivative with hydrochloric acid, concentrating and solidifying an aqueous solution of the obtained optically active monomethylcystine or a salt thereof, and in some cases, using an organic solvent. This is a method of isolating by washing in. However, when we isolated the compound according to this method, it was found that as the aqueous solution was concentrated, solids precipitated and became large lumps containing water, resulting in poor stirring. In addition, even if the concentration operation was continued, the solids adhered firmly to the wall surface and became completely fluid.
- the isolation method described in WO 01/72702 or the like cannot be said to be a method suitable for industrial production. Further, when the optically active methyl cysteine derivative is deprotected, and the resulting optically active ⁇ -methyl cysteine or a salt thereof is by-produced or mixed with a hardly soluble inorganic salt in a post-treatment step such as reaction or neutralization. However, these inorganic salts cannot be removed at all by the above-mentioned conventional method.
- A-Methylcysteine and its salts are unstable to oxidation and dimerize. Prone to sulfids. For example, in the case of cysteine having a similar structure, dimerization to cystine proceeds rapidly ("Protein Chemistry 1, Amino Acids'Peptides", Kyoritsu Shuppan, p. 326). Also in the present compound, if dimerization proceeds and a single disulfide is formed, its removal is not easy and it is difficult to avoid contamination of the product. Therefore, it is also important to establish a process that highly suppresses the formation and contamination of disulfide bodies.
- the racemic ⁇ -methyl cysteine derivative serving as a substrate must be simple and efficient to produce, and must be compatible with the substrate specificity of the enzyme and have high stereoselectivity. It is required that the compound has an appropriate protecting group or auxiliary group, and that the protecting group or auxiliary group can be easily removed after the enzymatic reaction.
- a suitable racemic ⁇ -methylcysteine derivative includes a ⁇ -rubumboylu- ⁇ -methylcysteine derivative.
- Hydantoinase known as a ring-opening hydrolase of hydantoin, has long been known to catalyze the reverse reaction of converting ⁇ -rubumboyl- ⁇ -amino acid to the corresponding 5-substituted hydantoin. It is expected that only one of the optical isomers of the racemic ⁇ -potassium rubamoyl-methyl cysteine derivative will be selectively converted to hydantoin using the enzyme and subjected to optical resolution.
- the optically active ⁇ -rubusmoyl- -methylcysteine derivative obtained by optical resolution can be easily converted to an optically active monomethylcysteine derivative by derivatized rubamoylation.
- optically active 5-methyl-5-thiomethylhydantoin derivative is an equivalent of the optically active ⁇ - methyl cysteine derivative and undergoes ring-opening hydrolysis and weakening rubamoylation. It can lead to optically active ⁇ _methylcysteine derivatives (having the opposite stereochemistry to those directly obtained by optical division).
- the racemic ⁇ -capitarum- ⁇ -methylcysteine derivative can be produced by combining the general chemical synthesis of amino acids with the ⁇ -capitarumylation reaction. —Methods for producing methylcysteine derivatives in short steps and in high yields have not yet been established.
- racemic N-potassium monomethyl cysteine derivative by the method described in this patent, we could obtain the desired compound in only 25% yield. I was told. That is, a method has been established for efficiently producing a racemic N-potassium-yl-disubstituted amino acid derivative, particularly a racemic ⁇ -potassium- ⁇ -methylcystine derivative in a small number of steps and in high yield. Absent.
- Japanese Patent Application Laid-Open No. 1-124398 discloses that a racemic ⁇ -force rubamoyl ruamino acid derivative is acted on by a hydantoinase to stereoselectively. A method for carrying out the splitting by cyclization is described. There is no mention or suggestion of the possibility of the reaction of the derivative. Summary of the Invention
- an object of the present invention is to provide an optically active L-form or D-form ⁇ -methylcysteine derivative or a salt thereof, which is useful as an intermediate for a drug or the like, from an inexpensive and easily available raw material, It is to provide a practical method for industrial production.
- the present inventors have conducted intensive studies in view of the above, and as a result, by reacting a hydantoinase on a racemic ⁇ -potassium rubamoyl- ⁇ -methylcysteine derivative or a salt thereof, the D-isomer is selectively cyclized, and D-5- methyl-5-thio-methylhydantoin induction, or a salt thereof and ⁇ - force Rubamoiru - alpha - and methyl one L- cysteine derivative or its salt, followed ⁇ - force Rubamoiru ⁇ - methyl one L one cysteine weakness derivative or its salt
- a method for obtaining a permethyl-L-cysteine derivative or a salt thereof by performing rubamoylation and deprotection of a sulfur atom has been found.
- the present inventors have found a method for obtaining a dimethyl-D-cystine derivative or a salt thereof by hydrolyzing a D-5-methyl-5-thiomethylhydantoin derivative or a salt thereof and deprotecting a sulfur atom. Furthermore, a method for easily producing racemic ⁇ -potassium rubamoyl-methyl cysteine derivative as a raw material of the above method in high yield has been established, and the present invention has been completed.
- the present invention provides a compound represented by the general formula (1):
- R 1 is an alkyl group having 1 to 20 carbon atoms which may have a substituent, an aralkyl group having 7 to 20 carbon atoms which may have a substituent, or a substituent. (Represents an aryl group having 6 to 20 carbon atoms which may be possessed) ⁇ —Rubamoy Ru-methyl cysteine derivative or its salt is treated with hydantoinase to selectively cyclize in D-form Characterized by the general formula (2):
- R 1 is the same as defined above, and a process for producing an N-potassium-l-methyl-L-cysteine derivative or a salt thereof.
- the present invention provides the N-potassium-l-bamoyl-a-methyl-L-cysteine derivative
- R 2 represents R 1 or a hydrogen atom
- R 2 represents R 1 or a hydrogen atom
- the present invention provides a method for treating an N-forcerubamoyl-a-methyl-L-cysteine derivative or a salt thereof, wherein R 1 in the formula (3) is a tertiary alkyl group having 4 to 15 carbon atoms, or a salt thereof.
- General formula (5) characterized in that the weakening and the deprotection of the sulfur atom are performed simultaneously.
- A-methyl-L-cysteine represented by the formula:
- the present invention provides the N-potassium-l-bamoyl-a-methyl-L-cysteine derivative (3) or a salt thereof, wherein cyclization and deprotection of a sulfur atom are carried out.
- the present invention relates to a method for producing 5-methyl-5-thiomethylhydantoin (6) or a salt thereof.
- the present invention provides a compound represented by the general formula (8), wherein the D-5-methyl-5-thiomethylhydantoin derivative (2) or a salt thereof is hydrolyzed, and if necessary, a sulfur atom is deprotected. ):
- R 1 in the above formula (2) is a tertiary alkyl group having from 15 to 15 carbon atoms is treated with an acid to simultaneously carry out a hydrolysis reaction and deprotection of a sulfur atom.
- the present invention provides a compound of the formula (8), wherein R 2 is the same as R 1 , wherein the ⁇ -methyl-D-cystine derivative or a salt thereof is converted into a compound by the general formula (10):
- the present invention also provides a compound represented by the formula (11), wherein the compound represented by the formula (2) is treated with an acid to deprotect a sulfur atom. And a method for producing methyl-5-thiomethylhydantoin or a salt thereof.
- These optically active 5-methyl-5-thiomethylhydantoin derivatives or salts thereof can be easily converted to optically active ⁇ -methylcysteine by hydrolysis, and, like optically active ⁇ -methylcysteine, can be used as pharmaceuticals. It can be suitably used as a synthetic intermediate such as.
- the present invention provides a method for crystallizing an optically active ⁇ -methyl cysteine or a salt thereof, comprising crystallization of the optically active ⁇ -methyl cysteine or a salt thereof from an aqueous solution of the optically active ⁇ -methyl cysteine or a salt thereof.
- the present invention provides the following formula (1 2)
- R 3 and R 4 are each independently an alkyl group having 1 to 20 carbon atoms which may have a substituent, an aralkyl group having 7 to 20 carbon atoms which may have a substituent Or a substituted or unsubstituted aryl group having 6 to 20 carbon atoms, which is a racemic 5,5-disubstituted hydantoin derivative or a salt thereof, especially the following formula (14):
- the present invention also relates to a method for producing a methylcysteine derivative or a salt thereof.
- the present invention provides a racemic compound represented by the above formula (1), a ⁇ -potassium rubamoyl- ⁇ -methylcysteine derivative or a salt thereof; an L form represented by the above formula (3) or (10) Or the D-form optically active N-potassium-alpha-methylcysteine derivative or a salt thereof; the D-form or the R-formula in the formula (2) or (7), wherein R 1 is a tertiary alkyl group having 4 to 15 carbon atoms.
- the present invention relates to an optically active monomethylcysteine derivative of D-form or a salt thereof; and an optically active 5-methyl-5-thiomethylhydantoin of L-form or D-form represented by the formula (6) or (11) or a salt thereof.
- R 1 has an alkyl group having 1 to 20 carbon atoms which may have a substituent, and has a substituent.
- alkyl group having 1 to 20 carbon atoms examples include linear alkyl groups such as methyl group, ethyl group, ⁇ -propyl group, ⁇ -butyl group, isopropyl group, isopropyl group, t-butyl group, neopentyl group, Examples include a branched alkyl group such as a t-pentyl group and a t-hexyl group, and an alkyl group having 1 to 10 carbon atoms is preferable.
- Examples of the aralkyl group having 7 to 20 carbon atoms include a benzyl group; and a methoxybenzyl group, a phenethyl group, a naphthylmethyl group, and the like, and preferably an ara / lequinole group having 7 to 15 carbon atoms. It is.
- Examples of the aryl group having 6 to 20 carbon atoms include a fuel group and a naphthyl group, and preferably an aryl group having 6 to 15 carbon atoms.
- the alkyl group, aralkyl group and aryl group may be unsubstituted or may have a substituent.
- substituents include an amino group, a hydroxyl group, an aryl group, an alkanol group, an alkenyl group, an alkyl group, an alkoxy group, a nitro group, and a halogen atom.
- aryl group as the substituent include an aryl group having 6 to 15 carbon atoms such as a phenyl group, a naphthyl group, a p-methylphenyl group, an m-methylphenyl group, and an o-methylphenyl group.
- alkanoyl group examples include alkanoyl groups having 2 to 10 carbon atoms such as an acetyl group, a propanoyl group and a butanoyl group.
- alkenyl group examples include alkenyl groups having 2 to 10 carbon atoms, such as an ether group and a propenyl group.
- alkynyl group examples include an alkynyl group having 2 to 10 carbon atoms such as an ethynyl group and a propynyl group.
- alkoxy group examples include an alkoxy group having 1 to 10 carbon atoms such as a methoxy group, an ethoxy group, an n-propoxy group, and an isopropoxy group.
- the halogen atom examples include a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
- 3 good carbon atoms 4-1 5 may have a substituent Kyua alkyl group Is preferred. Specific examples include a t-butyl group, a t-pentyl group, a t-hexyl group and the like, and more preferably a t-butyl group.
- R 3 and R 4 each independently have an optionally substituted alkyl group having 1 to 20 carbon atoms and a substituent.
- Examples of the alkyl group having 1 to 20 carbon atoms, the aralkyl group having 7 to 20 carbon atoms, and the aryl group having 6 to 20 carbon atoms include the same groups as those described in the description of R 1 above. .
- the alkyl group, aralkyl group, and aryl group may be unsubstituted or may have a substituent.
- substituents described in the description of R 1 the following formula (15):
- R 1 is the same as above, and preferred specific examples thereof are also the same as above.
- the racemic N-potassium monomethyl cysteine derivative (1) and the racemic N-potassium rubamoyl- ⁇ -amino acid derivative (13) may be a salt, and the salt represents a salt with a base.
- the salt with a base is not particularly limited.
- a salt with an alkali metal hydroxide sodium hydroxide, potassium hydroxide, lithium hydroxide, etc.
- an alkaline earth metal hydroxide calcium hydroxide, water And magnesium oxide
- R 1 is defined as in the compound represented by the formula (1) Same as the ones.
- R 3 and R 4 are the same as those defined for the compound represented by the formula (13).
- a compound in which one of R 3 and R 4 is a methyl group and the other is a methyl group substituted by the substituted thio group (15) is the compound (14).
- These 5,5-disubstituted hydantoin derivatives may be salts, and the salt represents a salt with a base and a salt on an imido group of a hydantoin ring.
- the salt with a base is not particularly limited, but, for example, a salt with an alkali metal hydroxide (sodium hydroxide, potassium hydroxide, lithium hydroxide, etc.); an alkaline earth metal hydroxide (calcium hydroxide hydroxide) And magnesium hydroxide).
- it is a salt with sodium hydroxide or a hydroxylating power.
- optically active N-potassium rubamoyl-methyl cysteine derivative represented by the formula (3) or (10) R 1 is the same as described above.
- optically active N-carbamoyl- ⁇ - methylcysteine derivatives may be salts, and the kind of the salts is the same as in the case of the compound represented by the formula (1).
- optically active ⁇ -methylcysteine derivatives represented by the above formulas (4) and (8) And R 2 represents R 1 or a hydrogen atom.
- R 1 is an alkyl group having 1 to 20 carbon atoms which may have a substituent, an aralkyl group having 7 to 20 carbon atoms which may have a substituent, or having a substituent.
- These optically active a-methylcysteine derivatives may be salts, and examples of the salts include salts with acids and salts with bases.
- Acids include hydrohalic acid (hydrochloric acid, hydrobromic acid, hydrofluoric acid, etc.), sulfonic acid (methanesulfonic acid, benzenesulfonic acid, p_toluenesulfonic acid, etc.), sulfuric acid, nitric acid, carboxylic acid (formic acid) Acetic acid, propionic acid, oxalic acid, trifluoroacetic acid and the like).
- hydrohalic acid hydrohalic acid, hydrobromic acid, hydrofluoric acid, etc.
- sulfonic acid methanesulfonic acid, benzenesulfonic acid, p_toluenesulfonic acid, etc.
- sulfuric acid nitric acid
- carboxylic acid carboxylic acid
- Acetic acid propionic acid
- oxalic acid trifluoroacetic acid and the like
- Examples of the base include organic bases (ammonia, triethylamine, aerin, pyridine, etc.), alkali metal hydroxides (sodium hydroxide, potassium hydroxide, lithium hydroxide, etc.), alkaline earth metal hydroxides (calcium hydroxide, Magnesium hydroxide, etc.).
- optically active 5_methyl_5-thiomethylhydantoin represented by the formula (6) or (11) may be a salt, and the kind of the salt is a compound represented by the formula (1). Is the same as
- the racemic N-potassium rubamoyl amino acid derivative (13) or a salt thereof is obtained by converting the racemic 5,5-disubstituted hydantoin derivative represented by the formula (12) or a salt thereof into an organic base or an alkanol. It can be produced by hydrolysis using a metal hydroxide.
- racemic 5,5-disubstituted hydantoin derivative (12) or a salt thereof as a raw material can be synthesized from the corresponding ketone by a Bucherer method well known to those skilled in the art.
- hydrolysis is carried out using an organic base or an alkali metal hydroxide as a base.
- the organic base is not particularly limited, but includes, for example, methylamine, dimethylamine, trimethylamine, ethynoleamine, getylamine, triethylamine, disopropylethylamine, pyridine, aniline and the like. These organic bases may be used alone or in combination of two or more.
- the alkali metal hydroxide include lithium hydroxide, sodium hydroxide, potassium hydroxide, cesium hydroxide and the like. These alkali metal hydroxides may be used alone or in combination of two or more.
- the base used for the hydrolysis is preferably an alkali metal hydroxide, more preferably sodium hydroxide or potassium hydroxide, from the viewpoint of yield and economy.
- the amount of the base used is not particularly limited, but is preferably 1 to 10 molar equivalents, more preferably 2 to 5 molar equivalents, based on the substrate.
- the reaction solvent may be water alone or a mixture of water and an organic solvent.
- the organic solvent to be mixed with water as the solvent is not particularly limited, and examples thereof include a hydrocarbon solvent, an ester solvent, an ether solvent, an alcohol solvent, a nitrile solvent, and an amide solvent. Preferred are hydrocarbon solvents.
- the hydrocarbon solvent is not particularly limited, but includes, for example, toluene, benzene, xylene, hexane, cyclohexane, heptane, and the like, and any one of these may be used alone, Alternatively, two or more kinds may be used in a mixture at an arbitrary ratio. Preferably it is toluene.
- ester solvent examples include ethyl formate, methyl acetate, ethyl ethyl acetate, isopropyl acetate, methyl propionate, and the like.
- ether solvents examples include getyl ether, tetrahydrofuran, 1,4-dioxane, methyl t-butyl ether, and the like.
- alcohol solvents examples include methanol, ethanol, 1-propanol, isopropanol, 1-butanol, 2-butanol and the like.
- nitrile-based solvents examples include acetoetrile, propionitrile and the like.
- amide solvents examples include dimethylformamide and dimethylacetamide.
- the water used for the reaction is preferably 0.1 to 100 times the weight of the substrate, and more preferably 0.1 to 10 times the weight, more preferably 0.1 to 10 times the weight, in terms of yield and volumetric efficiency. Preferably it is 0.2 to 3 times the weight.
- reaction temperature depends on the type of the substrate and the amount of the sample, and cannot be specified unconditionally, but can be selected from the conditions of 50 ° C to 150 ° C, preferably from 80 ° C to 110 ° C, The temperature is more preferably from 85 ° C to 100 ° C.
- the reaction time depends on the type of the substrate, the amount of the sample, and the reaction temperature, and cannot be specified unconditionally.However, the reaction is preferably carried out for 1 to 50 hours, and more preferably for obtaining a product with a high yield. 2 to 24 hours.
- the reaction may be used for the next reaction as it is, or may be isolated by extraction and purification after neutralization by adding an acid. Alternatively, the compound may be isolated by filtering the reaction mixture.
- a racemic 5-methyl-5-thiomethylhydantoin derivative represented by the above formula (14) is produced from the thioacetone derivative by the Bucherer method using the compound represented by the above formula (1) in the same manner as described above. It can be produced by hydrolyzing it.
- a racemic N-potassium rubamoyl-methyl cysteine derivative (1) or a salt thereof is selectively cyclized with a hydantoinase in a D-isomer to form a D-5-methyl-15-thiomethylhydantoin derivative (2).
- a method for synthesizing a salt thereof and an N-potassium- alpha -methyl-l-cysteine derivative (3) or a salt thereof is synthesizing a salt thereof and an N-potassium- alpha -methyl-l-cysteine derivative (3) or a salt thereof.
- the hydantoinase is an enzyme having an activity of hydrolyzing a 5-substituted hydantoin derivative or a salt thereof to generate a ⁇ -potency rubamoyl-a-amino acid derivative.
- the present enzyme generally cyclizes an amino acid derivative of rubamoyl monoamino acid to produce a 5-substituted hydantoin derivative as a reverse reaction of the hydrolysis reaction (Japanese Unexamined Patent Publication No. 1-12). No. 4 389 9).
- the hydantoinase catalyzing the D-selective cyclization reaction used in the present invention can be any of animals, plants, or microorganisms, but is preferably derived from microorganisms for industrial use.
- the microorganism serving as the enzyme source any microorganism having the ability to produce the enzyme can be used.
- the following known microorganisms having the ability to produce the enzyme can be mentioned.
- bacteria belonging to the genus Acetobacter r bacteria belonging to the genus Acetobacter r), genus Achromobacter, genus Aeronobacter (Ae robacte rj, aku, 'Ag robacterium', genus Alcaligenes, genus Arsulobacter (A rthrobacter), Bacillus, Previbacterium (Brevibacteri um), Corynebacterium (Corynebacteri um), Enterobacter (En terobacter), Erwinia (Erwinia), Escherichia scherichia), Klebsiella, Microbacterium (Microbacteri umj Crococcus), Protaminobacterium, Proteus (Pr), Bacillus, Previbacterium (Brevibacteri um), Corynebacterium (Corynebacteri um), Enterobacter (En terobacter), Erwinia (Erwinia), Escherichia scherichia), Klebs
- an enzyme derived from a microorganism belonging to the genus Agrobacterium (Agrobacterium), the genus Bacillus (Bacillus), the genus Pseudomonas (Pseudomonas), or the genus Rhizobium (Rhizobium) is used. More preferably, Agroba battery species (Ag rob a c t e r
- KNK 712 (FE RM BP- 1900), Batinoles, Spices (Bacillussp.) KNK 245 (FERM BP-486 3), Pseud omo nasputida IF01 2996, Pseud omo nassp. KNKO 03A (FERM B P-31 81) or Rhizobium 'sp. (R hizobi um sp.) KNK 141 5 derived enzymes.
- Agrobacterium sp. KNK 712 is the accession number of FERM BP-1900, dated May 31, 1988; Bacillus sp.
- KNK 245 FERM BP- 4863, with accession number January 1, 1994; Pseudomonas ⁇ Species Pseud omo nassp.
- KNKO 03A is the accession number of FERM BP-3181, December 1990 1 date; respectively, deposited internationally at the National Institute of Advanced Industrial Science and Technology Patent Organism Depositary at the National Institute of Advanced Industrial Science and Technology at 1-chome, Tsukuba East, Ibaraki, Japan, based on the Budapest Treaty .
- the microorganism may be a wild-type strain, or may be a mutant strain whose hydantoinase activity has been enhanced by mutagenesis. Furthermore, a transformed microorganism prepared by using a method such as genetic recombination to produce high hydantoinase derived from the above microorganism may be used.
- a recombinant plasmid with an appropriate vector is used. It is obtained by constructing and transforming an appropriate host bacterium using this. Recombinant DNA technology is well known in the art, for example, Molecular Cloning 2nd Edition (Cold Spring Harbor Laboratory Press, 1989), Current Protocolsin Mo lecular Biology ( G reene Pu blishing As sociates and Wi 1 ey—Interscience).
- the transformed microorganisms that produce high hydantoinase obtained in this manner include the Bacillus species described in WO 96/20275. ssp.) Escherichiacoli HB 101 TH 104 (F ERM BP—4864) containing the hydantoinase gene derived from KN 245 (F ERM BP— 4863), Agrobacterium sp. sp.) Escherichiacoli HB 101 AH 1043 (FE RM B P-4865) containing the hydantoinase gene derived from KNK 712 (FER MB P_1900), or Pseud om onass p. ) Escherichia coli HB101 PHD301 (FERMBP-4866) containing the hydantoinase gene derived from KNKO 03A (FERMBP_3181).
- Escherichiacoli HB101 PTH104 is the accession number of FERM BP-4864, dated January 2, 1994; Escherichiacoli HB10 1 pAH1043 is FERM BP-4865 Escherichiacoli HB101p PHD 301 is the accession number of FERM BP_4866, dated January 2, 1994; January 2, 1994; respectively, Japan It has been internationally deposited at the Patent Organism Depositary of the National Institute of Advanced Industrial Science and Technology at Tsukuba East 1-chome 1 Chuo No. 6 in Ibaraki Prefecture based on the Budapest Convention.
- the production of hydantoinase by the microorganism exhibiting the above-mentioned hydantoinase activity or the above-mentioned transformed microorganism may be carried out by culturing in a normal nutrient medium as described in, for example, WO 96/20275. Depending on the conditions, a treatment for inducing the enzyme can be performed. Enzyme induction can be performed, for example, by adding peracil to a culture medium and culturing the medium.
- the hydantoinase produced by the above microorganism can be used not only as the enzyme itself, but also as a microorganism having the enzyme activity or a processed product thereof.
- the processed microorganism is, for example, a crude extract, a freeze-dried organism of cultured cells, an acetone-dried organism, or a crushed product of those cells.
- they can be used as immobilized enzymes obtained by immobilizing the enzymes themselves or the cells as they are by known means.
- the enzyme reaction can be performed in a more severe temperature range, and the reaction can proceed more efficiently.
- the enzyme can be used repeatedly, and that the production process can be simplified, thereby reducing production costs.
- the immobilization can be performed by a method known to those skilled in the art, such as a cross-linking method, a covalent bonding method, a physical adsorption method, an entrapment method, or the like.
- the support used for immobilization of the enzyme include phenol formaldehyde anion exchange resin such as Duo 1ite A-568 or DS 17186 (Rohm 'and' Haas Co., Ltd.), Amber 1ite Polystyrene resins such as IRA935, IRA945, IRA901 (Rohm-and-Haas: registered trademark), Lewa tit OC 1037 (Bayer: registered trademark), and Diaion EX-05 (Mitsubishi Chemical: registered trademark)
- a support such as DEAE-cellulose can also be used.
- the method described in WO 96Z20275 can be used. That is, a culture solution of a strain having a hydantoinase activity is collected, the cells are disrupted by ultrasonic waves or the like, and then, for example, an anion exchange resin Duolite A-568 is added to the obtained enzyme solution, followed by stirring to adsorb the enzyme. Can be done.
- a crosslinking reagent such as daltaraldehyde is added to the resin to which the enzyme is adsorbed and the mixture is stirred to perform a crosslinking treatment, thereby further improving the stability. After these treatments, the resin is collected by filtration and washed to obtain immobilized hydantoinase.
- the enzyme reaction of the present invention can be performed by the following method.
- the reaction is carried out in an aqueous medium in the presence of the above-mentioned hydantoinase, using a racemic N-potassium rubamoyl-methyl cysteine derivative represented by the above general formula (1) or a salt thereof as a substrate.
- the reaction temperature is adjusted at an appropriate temperature of 10 ° C or more and 80 ° C or less, preferably 20 ° C or more and 60 ° C or less, and pH 4 or more and 9 or less, preferably pH 5 or more and 8 or less.
- the substrate can be added continuously.
- the reaction can be performed in a batch or continuous mode. Further, the reaction of the present invention can be carried out using an immobilized enzyme, a membrane reactor, or the like.
- the aqueous medium examples include water, buffers (eg, phosphate buffer, Tris buffer, carbonate buffer, etc.) and solvents containing water-soluble organic solvents (eg, ethanol, methanol, acetonitrile, etc.). it can.
- the aqueous medium can be used as a two-phase system with an organic solvent that is hardly soluble in water (eg, ethyl acetate, butyl acetate, toluene, chloroform, n-hexane, etc.). If necessary, an antioxidant, a surfactant, a coenzyme, a metal and the like can be added.
- racemic N-potamoyl- ⁇ -methylcysteine derivative (1) or a salt thereof has only the D-form cyclized, and the D-5-methyl-15-thiomethylhydantoin derivative (2) Or a salt thereof, and a ⁇ -force rubamoyl-1- ⁇ -methyl-L-cysteine derivative (3) or a salt thereof.
- the resulting ⁇ -active rubamoyl- ⁇ -methyl-1-L-cysteine derivative (3) or a salt thereof may be used as it is in the reaction solution for the de-active rubamoylation reaction, or may be subjected to a conventional separation method, for example, extraction, concentration, crystallization. Separation and purification can be performed by using, for example, or column chromatography, or a combination thereof.
- R 1 is a t-butyl group
- R-molybamoyl-S-t-butyl- ⁇ -methylcysteine is used as a substrate for the D-selective cyclization reaction with hydantoinase
- the insoluble matter is obtained after the reaction.
- D-5-methyl-5-t-butylthiomethylhydantoin which precipitates as, can be easily removed by filtration.
- the obtained filtrate containing N-potassium-l-methyl-L-cysteine may be used as it is in the next step, or may be purified and used in the next step.
- the compound can be obtained by precipitating crystals by making H acidic and filtering the crystals.
- D-5-methinolay 5-t-butylthiomethylhydantoin precipitated as an insoluble component may be used as it is in the next step, or may be dissolved in an aqueous alkali solution. It can be used in the next step as an alkaline solution. Crystals can also be obtained by neutralizing an alkaline aqueous solution, but the method is not limited to these methods.
- the protecting group for the sulfur atom is selected from those represented by R 1 above.
- deprotection of rubamoylation (deprotection of an amino group) and deprotection of a sulfur atom may be performed together, or one of them may be performed step by step, followed by removal of the remaining protective groups. Good.
- An appropriate method for deprotection may be selected depending on the protecting group and the purpose.
- Examples of the acid used in the present method include hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid, acetic acid, and trifluoroacetic acid. Any one selected from the above may be used alone, or Two or more kinds may be used by mixing at an arbitrary ratio. From the viewpoint of reactivity and economy, hydrochloric acid or hydrobromic acid is preferred, and hydrochloric acid is more preferred. As hydrochloric acid and hydrobromic acid, commercially available concentrated hydrochloric acid and concentrated hydrobromic acid can be used also as a reaction solvent. Water or an organic solvent may be added, but from the viewpoint of reactivity, it is also preferable to double as a reaction solvent.
- the reaction conditions include, for example, treating N-carbamoyl-1-S-t-butyl-1 ⁇ -methylcysteine, in which the protective group for the sulfur atom is a t-butyl group, with hydrochloric acid,
- the reaction temperature is preferably from 70 ° C. to 180 ° C., more preferably from 90 ° C. to 150 ° C.
- the reaction time is preferably about 2 to 4 days when the reaction is carried out at, for example, 100 ° C. to 110 ° C. and normal pressure. By performing the reaction at a higher temperature using a reactor, the reaction time can be shortened.
- R 2 is the same as R 1 in the above formula (1).
- a method for obtaining a methyl-L-cysteine derivative or a salt thereof, followed by deprotection of a sulfur atom to obtain ⁇ -methyl-L-cystine or a salt thereof represented by the above formula (5) will be described.
- the derivatized rubamoylation is not particularly limited as long as it can remove the derivatized rubamoyl group, and examples thereof include a nitrite oxidation method, an alkali hydrolysis method and an acid hydrolysis method.
- the protecting group on the sulfur atom is a tertiary alkyl group such as t_butyl group
- the acid hydrolysis method using hydrochloric acid or the like tends to promote the deprotection on the sulfur atom. If desired, it is preferable to use another method.
- reaction conditions used for ordinary derubbing of rubamoyl can be used.
- nitrite alone or a combination of a nitrite salt and an appropriate acid can be used, but a combination of a nitrite and an acid is preferably used.
- nitrite examples include sodium nitrite, potassium nitrite, calcium nitrite, cesium nitrite, magnesium nitrite, barium nitrite, and the like, and preferable are nitrite nitrite and sodium nitrite.
- acid to be combined acetic acid, hydrochloric acid, sulfuric acid, hydrobromic acid and the like are preferable, and hydrochloric acid is particularly preferable.
- the solvent is not particularly limited, but water or alcohol (eg, methanol, ethanol, isopropanol, etc.) is preferably used in view of the solubility of the substrate.
- the reaction temperature of the nitrite oxidation method is preferably in the range of 15 ° C.
- the alkali used in the alkali hydrolysis method is not particularly limited, but is preferably, for example, sodium hydroxide, lithium hydroxide, potassium hydroxide, barium hydroxide, magnesium hydroxide, calcium hydroxide, or the like, and more preferably lithium hydroxide. is there.
- the reaction temperature of the hydrolysis is preferably in the range of 150 ° C to 150 ° C.
- the temperature is more preferably in the range of 80 ° C to 120 ° C from the viewpoints of productivity and yield improvement.
- a compound in which R 2 is the same as R 1 in the formula (1) may be used as it is in the next step, or may be purified and used in the next step.
- purification for example, when R 2 is a t-butyl group, the pH of the reaction solution after alkali hydrolysis is lowered by adding an acid, so that R 2 in the above formula (4) is The methyl-L-cysteine derivative which is a tyl group or a salt thereof can be obtained as crystals.
- the alkali used for the alkali hydrolysis is arbitrarily selected from sodium hydroxide, lithium hydroxide, potassium hydroxide, barium hydroxide, magnesium hydroxide, calcium hydroxide and the like.
- the acid added to the reaction solution after the alkali hydrolysis include hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid, acetic acid, trifluoroacetic acid, and the like, and any one selected from the above may be used alone. It may be used, or two or more kinds may be mixed and used at an arbitrary ratio, but the inorganic salt generated during neutralization has good solubility in water and is easy to desalinate.
- the term “neutralization” as used herein means that the pH of the reaction solution is adjusted to a region where crystals precipitate.
- the upper limit of pH is preferably 9.5 or less, and preferably 7.5 or less, in order to obtain a high yield of a methyl-L-cystine derivative or a salt thereof in which R 2 is a t-butyl group in the form of crystals. 0 or less is more preferable.
- the lower limit of pH is usually 1.0 or more, preferably 2.0 or more, and more preferably 3.0 or more.
- the reaction solution may be used as it is, or the ⁇ -methyl-L-cysteine derivative may be isolated, and then used as a protective group.
- the sulfur atom can be deprotected under the appropriate reaction conditions.
- the sulfur atom can be deprotected by treating with an acid.
- the acid include hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid, acetic acid, trifluoroacetic acid and the like. Any one selected from the above may be used alone, or two or more may be used arbitrarily. Mix at the ratio of May be used. Preferred is hydrochloric acid or hydrobromic acid, and more preferred is hydrochloric acid.
- hydrochloric acid or hydrobromic acid commercially available concentrated hydrochloric acid or concentrated hydrobromic acid can be used also as a reaction solvent. Water or an organic solvent may be added, but from the viewpoint of reactivity, it is also preferable to double as a solvent.
- the reaction temperature is preferably 50 ° C to 120 ° C, more preferably 80 ° C to 100 ° C.
- N-potassium-l-methyl-1-L-cystine derivative represented by the formula (3) or a salt thereof is passed through L-5-methyl-5-thiomethylhydantoin (6) or a salt thereof.
- a method for producing Hi-methyl-L-cysteine (5) or a salt thereof according to the present invention will be described.
- Examples of the acid used include hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid, acetic acid, trifluoroacetic acid and the like. Any one selected from the above may be used alone, or two or more kinds may be used. May be mixed at an arbitrary ratio.
- it is hydrochloric acid.
- hydrochloric acid or hydrobromic acid commercially available concentrated hydrochloric acid or concentrated hydrobromic acid can be used also as a reaction solvent. Water or an organic solvent may be added, but from the viewpoint of reactivity, it is preferable to also serve as a reaction solvent.
- the reaction temperature is not particularly limited, but mild conditions are preferable for suppressing the hydrolysis of L-5-methyl-5-thiomethylhydantoin (6) or a salt thereof, for example, 0 ° C to 1 ° C.
- the reaction may be performed for several hours at a temperature of 00 ° C, preferably 60 ° C to 90 ° C, and the reaction may be stopped when the target product becomes a main product.
- the power used is not particularly limited.
- sodium hydroxide examples include sodium hydroxide, potassium hydroxide, lithium hydroxide, magnesium hydroxide, barium hydroxide, and calcium hydroxide.
- sodium hydroxide, potassium hydroxide, or hydroxide is preferred in terms of availability and price. Lithium is preferred.
- the reaction temperature at the time of the cyclization is preferably from 0 ° C to 100 ° C, more preferably from 60 ° C to 90 ° C.
- the solvent may be water alone or a mixed solvent with an organic solvent. Preferably, it is water alone.
- the L-5-methyl-5-thiomethylhydantoin derivative (7) or a salt thereof may be used in the next step as it is, may be used in the next step after extraction with an organic solvent, or may be used alone by crystallization or the like. After separation, it may be used in the next step.
- Examples of the acid to be used include hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid, acetic acid, trifluoroacetic acid and the like. Any one selected from the above may be used alone, or two or more kinds may be used in an arbitrary ratio. May be used as a mixture. Hydrochloric acid is preferred in terms of yield and price.
- the acid treatment can be suitably performed under the same conditions as in the case where the above-mentioned deprotection and cyclization are performed in one step.
- L-5-Methyl-5-thiomethylhydantoin (6) or a salt thereof obtained as described above is converted into ⁇ -methyl-L-cysteine (5) or a salt thereof by hydrolysis with an acid or alkali. it can.
- Hydrolysis with an acid is preferred.
- the acid include hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid, acetic acid, trifluoroacetic acid and the like, and any one selected from the above may be used alone, or two or more kinds may be used at an arbitrary ratio. May be used as a mixture.
- Hydrochloric acid or hydrobromic acid is preferred, and hydrochloric acid is more preferred.
- the alkali metal for example, sodium hydroxide, potassium hydroxide, lithium hydroxide and the like are preferable.
- R 2 is Formula (1) to your Keru as R 1
- R 1 The same is true for the method for producing methyl-D-cystine or a salt thereof by deprotecting the sulfur atom of a methyl-D-cystine derivative or a salt thereof. explain about.
- the hydrolysis is usually performed using an alkali.
- the alkali used for the hydrolysis is not particularly limited, and examples thereof include sodium hydroxide, potassium hydroxide, lithium hydroxide, barium hydroxide, magnesium hydroxide, and calcium hydroxide. , Potassium hydroxide and lithium hydroxide.
- the solvent may be water alone or a mixed solvent with an organic solvent. Preferably, it is water alone.
- the reaction temperature is preferably from 15 ° C to 150 ° C, more preferably from 80 ° C to 120 ° C.
- R 2 is a t-butyl group
- the obtained ⁇ -methyl-S-t-butyl-D-cysteine is converted into a crystal by adding an acid to the reaction solution after the hydrolysis reaction; Can be obtained.
- the acid used here is not particularly limited as long as it can lower the pH of the reaction solution.
- the acid include hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid, acetic acid, trifluoroacetic acid and the like. Any one selected may be used alone, or two or more may be used in a mixture at an arbitrary ratio.
- hydrochloric acid because inorganic salt impurities generated during neutralization have good solubility in water and are hardly mixed into crystals.
- neutralization means that the pH of the reaction solution is adjusted to a region where crystals precipitate.
- the upper limit of pH is preferably 9.5 or less, more preferably 7.0 or less.
- the lower limit of pH is usually 1.0 or more, preferably 2.0 or more, and more preferably 3.0 or more.
- the obtained compound in which R 2 is the same as R 1 in the above formula (8) can be converted to ⁇ -methyl-D-cystine (9) or a salt thereof by deprotecting the sulfur atom.
- the method of deprotection is selected according to the protecting group on the sulfur atom, but when a tertiary alkyl group such as t-butyl is used as the protecting group, treatment with an acid is performed. Can be easily deprotected.
- Examples of the acid used in the present method include hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid, acetic acid, and trifluoroacetic acid. Any one selected from the above may be used alone, or Two or more kinds may be used by mixing at an arbitrary ratio. From the viewpoint of reactivity and economy, hydrochloric acid or hydrobromic acid is preferred, and hydrochloric acid is more preferred. When hydrochloric acid or hydrobromic acid is used, commercially available concentrated hydrochloric acid or concentrated hydrobromic acid can be used also as a reaction solvent. Water or an organic solvent may be added, but from the viewpoint of reactivity, it is preferable to also serve as a solvent.
- the reaction temperature is preferably from 70 ° C to 180 ° C, more preferably from 90 ° C to 150 ° C.
- R 1 in the above formula (2) is a tertiary alkyl group having 4 to 15 carbon atoms represented by a t-butyl group
- ⁇ -methyl-D-cis can be treated in one step by treating with an acid.
- Tin (9) or a salt thereof can be obtained.
- Examples of the acid used here include hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid, acetic acid, trifluoroacetic acid and the like. Any one selected from the above may be used alone, or two or more may be used. The above may be mixed and used at an arbitrary ratio. Preferably, it is hydrochloric acid or hydrobromic acid, and more preferably, hydrochloric acid.
- hydrochloric acid or hydrobromic acid commercially available concentrated hydrochloric acid or concentrated hydrobromic acid can be used also as a reaction solvent. Water or an organic solvent may be added, but from the viewpoint of reactivity, it is preferable to also serve as a solvent.
- the reaction temperature is preferably from 70 ° C to 180 ° C, more preferably from 90 ° C to 150 ° C.
- D_5-methyl-5-thiomethylhydantoin derivative (2) or a salt thereof is subjected to deprotection of a sulfur atom to obtain D-5-methyl-5-thiomethylhydantoin (11) or a salt thereof.
- a method for producing 1-methyl-D-cystine (9) or a salt thereof by hydrolyzing the compound will be described.
- D-5-methyl-5-thiomethylhydantoin derivative (2) or a salt thereof A method for selectively deprotecting the sulfur atom of to obtain D-5-methyl-5-thiomethylhydantoin (11) or a salt thereof will be described.
- the protective group for a sulfur atom is a tertiary alkyl group such as a t-butyl group, deprotection can be easily performed by treating with an acid.
- Examples of the acid used include hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid, acetic acid, trifluoroacetic acid and the like. Any one selected from the above may be used alone, or two or more kinds may be used. May be mixed at an arbitrary ratio. Preferably, it is hydrochloric acid.
- hydrochloric acid or hydrobromic acid commercially available concentrated hydrochloric acid or concentrated hydrobromic acid can be used also as a reaction solvent. Water or an organic solvent may be added, but from the viewpoint of reactivity, it is also preferable to double as a solvent.
- the reaction condition is not particularly limited as long as it is a relatively mild condition under which hydrolysis is suppressed and D_5-methyl-5-thiomethylhydantoin (11) can be obtained with good selectivity.
- the reaction may be performed for several hours at or below C, and the reaction may be stopped when the target product becomes the main product.
- D-5-methyl-5-thiomethylhydantoin (11) or a salt thereof is hydrolyzed to produce ⁇ -methyl-D-cysteine (9) or a salt thereof.
- the hydrolysis can be either acid hydrolysis or alkali hydrolysis.
- examples of the acid include hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid, acetic acid, trifluoroacetic acid and the like, and any one selected from the above may be used alone. Good, or two or more kinds may be mixed and used in an arbitrary ratio. Hydrochloric acid or hydrochloric acid is preferred from the viewpoint of reactivity and economy, and hydrochloric acid is more preferred.
- the reaction temperature is preferably from 70 ° C. to 180 ° C., and more preferably from 90 ° C. to 150 ° C.
- the reaction time is, for example, about 2 to 4 days when the reaction is carried out at 100 ° C. to 110 ° C. and normal pressure, and the reaction is carried out at a higher temperature using a pressure-resistant reactor. Time can be reduced.
- the carbamoylation of the ⁇ -methyl-D-cysteine derivative (8) or a salt thereof can be carried out using an alkali metal salt of a succinic acid and an acid.
- the metal salts of cyanic acid include potassium disocyanate, potassium cyanate, and sodium cyanate.
- the acid include hydrochloric acid, sulfuric acid, hydrobromic acid, nitric acid, acetic acid, trifluoroacetic acid and the like. Using these, the compound is subjected to ordinary reaction for the reaction of levamoylation (for example, in an aqueous solvent at 0 to 100 ° C.) to form the levavamoyl.
- the cyclization of the N-potamoyl- ⁇ -methyl-D-cysteine derivative (10) or a salt thereof and the deprotection of a sulfur atom are carried out by the above-mentioned ⁇ -potato rubamoyl-h-methyl-L-cystine derivative (3) or a salt thereof.
- the conversion can be carried out in the same manner as in the method described for the conversion to L-5-methyl-5-thiomethylhydantoin (6).
- optically active ⁇ -methyl cysteine or a salt thereof is not particularly limited, and examples thereof include optically active methyl cysteine, a salt of an optically active ⁇ -methyl cysteine with an acid, and a salt of an optically active ⁇ -methyl cysteine with a base. Is preferably a salt with an acid. Further, the optically active methyl cysteine may be either an L-form or a D-form.
- the acid of the salt with the above-mentioned acid include hydrohalic acid, sulfonic acid, sulfuric acid, nitric acid, carboxylic acid and the like, preferably hydrohalic acid.
- hydrohalic acid examples include hydrochloric acid, hydrobromic acid, hydrofluoric acid and the like. But preferably hydrochloric acid.
- Examples of the sulfonic acid include methanesnolephonic acid, benzenesulfonic acid, and -toluenesulfonic acid
- examples of the carboxylic acid include formic acid, acetic acid, propionic acid, oxalic acid, and trifluoroacetic acid.
- examples of the base of the salt with the base include ammoea, triethylamine, arin, pyridine and the like.
- the method for preparing the aqueous solution of optically active ⁇ -methylcysteine or a salt thereof is not particularly limited.
- it is an aqueous solution obtained by appropriately converting and deprotecting an ⁇ -methylcysteine derivative or a salt thereof or a protected form obtained by the above-mentioned conventional techniques 1) to 6).
- it may be an aqueous solution of the compound obtained according to the method described in the present specification.
- it is an aqueous solution of optically active ⁇ -methylcysteine or a salt thereof produced by the method described in the present specification.
- an aqueous solution of optically active ⁇ -methylcysteine or a salt thereof is concentrated in the presence of an organic solvent, thereby removing water outside the system and replacing the water with an organic solvent.
- the compound can be prevented from agglomerating, and a slurry that can be easily taken out and filtered can be obtained.
- After the obtained slurry is filtered, washed and dried, it is possible to obtain optically active ⁇ -methylcysteine or a salt thereof as crystals.
- the aqueous solution of the optically active sodium methyl cysteine or a salt thereof may be preliminarily concentrated before carrying out the present crystallization method. In this case, it is preferable to concentrate the aqueous solution so that the weight concentration of the compound becomes 10% by weight or more, more preferably 30% by weight or more.
- the type of the organic solvent to be replaced is not particularly limited, but is preferably a solvent that can azeotrope with water and has a composition of water of 5.0% by weight or more at the time of azeotropic distillation. Further, an organic solvent having low or no compatibility with water is more preferable.
- organic solvent having low or no compatibility with water examples include a hydrocarbon solvent, an ester solvent, and an ether solvent.
- Hydrocarbon-based organic solvents are preferred because they have low compatibility with water, low solubility of optically active methyl cysteine or a salt thereof, and easy recovery and reuse of the solvent.
- the hydrocarbon organic solvent is not particularly limited, for example, toluene, One of zen, xylene, hexane, cyclohexane, and heptane may be used alone or in combination of two or more.
- toluene is used from the viewpoint of economy.
- ester solvent include ethyl acetate, isopropyl acetate, isobutyl acetate and the like.
- ether solvent examples include dipropyl ether, dibutyl ether, 1,4-dioxane, and methyl t-butyl ether.
- solvents may be used singly or as a mixture of the same or different solvents at an arbitrary ratio.
- the replacement with the organic solvent may be performed at once, or may be performed in a plurality of times.
- the amount of the organic solvent to be replaced cannot be said unconditionally because it differs depending on the type of the organic solvent, the degree of reduced pressure of the concentration, and the internal temperature.
- the weight is preferably 0.1 to 100 times the weight, more preferably 0.2 to 10 times the weight of the weight.
- the concentration of the optically active ⁇ -methyl cysteine or a salt thereof is 0.1 to 0.1% when the optically active ⁇ -methyl cysteine or a salt thereof is crystallized while removing water from the system. 70% by weight, preferably 1-70% by weight.
- the amount of water finally remaining after water is removed from the system by the above operation is preferably 100% by weight or less based on the optically active ⁇ -methylcysteine or a salt thereof. From the viewpoint of properties, filterability, crystallization rate, and fluidity of the slurry, it is more preferable to remove water out of the system to 40% by weight or less.
- the evaporation rate at the time of concentration depends on the capacity of the equipment and cannot be specified unconditionally.However, when the evaporation rate is increased, the foaming becomes severe and the fluidity of the obtained slurry becomes extremely poor, and the slurry is agglomerated. There is a tendency. Therefore, it is preferable to control the evaporation rate to 1000 LZhhm 2 or less as a rate per unit evaporation area and unit time. 600 L / h ⁇ m 2 or less is more preferable, 300 L / h ⁇ m 2 or less is more preferable, and 100 L / h ⁇ m 2 or less is particularly preferable.
- the degree of reduced pressure at the time of concentration after the addition of the organic solvent is usually 50 OmmHg or less, preferably 20 OmmHg or less.
- the lower limit is not particularly limited, but is usually 0.1 ImmHg or more.
- the temperature at the time of concentration depends on the degree of decompression and the capacity of the apparatus, but is 0 ° C to 150 ° C, preferably 10 ° C, in order to obtain easy-to-handle, high-quality crystals. ° C to 100 ° C, more preferably 30 to 70 ° C.
- the amount of water finally remaining is preferably 100% by weight based on the optically active methyl cysteine or a salt thereof. / Q or less, and it is more preferable to remove water out of the system to 40% by weight or less from the viewpoint of the amount of the inorganic salt to be removed.
- Type of organic solvent substitution is not particularly limited, soluble or inorganic salt flame is insoluble, and, in that _ methyl cis Tin hydrochloride optically active ⁇ has a soluble property, water miscible Preferred organic solvents are preferred. More preferably, it is an alcohol-based solvent alone, an ether-based solvent compatible with water alone, or a solvent in which each is arbitrarily mixed.
- the alcohol-based solvent include methyl alcohol, ethyl alcohol, ⁇ -propyl alcohol, isopropyl alcohol, ⁇ -butyl alcohol, iso-butino real alcohol, sec-butino real alcohol, t-butyl alcohol, and the like. One of these may be used alone, or two or more of them may be used in a mixture at any ratio.However, it reduces the side reactions such as dehydration efficiency, economy, and esterification. From the viewpoint, isopropyl alcohol is preferred.
- ether solvent compatible with water examples include getyl ether, diisopropyl / ether, tetrahydrofuran, 1,4-dioxane, and methyl-t-butyl ether. One of these may be used singly or two or more may be mixed at an arbitrary ratio. And preferably tetrahydrofuran.
- the method of crystallizing the optically active ⁇ -methylcysteine or a salt thereof from the filtrate obtained after removing the hardly soluble inorganic salt is not particularly limited, and examples thereof include general methods such as adding a poor solvent, cooling, or concentrating. Although a simple crystallization operation can be performed, a method of adding a poor solvent is preferable.
- the poor solvent is not particularly limited, and examples thereof include a hydrocarbon-based solvent, an ester-based solvent, and an ether-based solvent that is incompatible or low in water. Hydrocarbon solvents and ester solvents are preferred from the viewpoint of the amount of precipitated crystals and the purity. More preferred are hydrocarbon solvents.
- the hydrocarbon solvent is not particularly limited, but includes, for example, toluene, benzene, xylene, hexane, cyclohexane, heptane, etc., and is preferably toluene, xylene, hexane, heptane, and more preferably. It is toluene.
- the ester solvent include, but are not particularly limited to, methyl acetate, ethyl acetate, propyl acetate, methyl propionate, ethyl propionate, and the like, and preferably ethyl ester.
- ether-based solvent which is incompatible or low in water are not particularly limited, and include, for example, dipropynoleatenole, dibutynoleatenole, 1,4-dioxane, methinole t-butyl ether and the like.
- solvents may be used singly or as a mixture of the same or different solvents at an arbitrary ratio.
- the concentration of the compound when crystallizing optically active monomethylcysteine or a salt thereof varies depending on the temperature, the solvent ratio, and the like, but is usually 0.1 to 70% by weight, and preferably 0.1 to 70% by weight, based on the whole solution. It is 1 to 70% by weight, more preferably 2 to 70% by weight. According to the crystallization method of the present invention, high-purity optically active monomethyl cysteine or a salt thereof can be satisfactorily obtained in an industrially practicable process.
- the content of the corresponding disulfide compound in the crystals obtained by the crystallization method of the present invention is 1.0 mol% or less, preferably 0.5 mol% or less, more preferably 0.1 mol% or less. .
- a preferred form for obtaining an optically active ⁇ -methylcysteine or a salt thereof having a low content of a disulfide compound is a salt with an acid, more preferably a salt with hydrohalic acid, and still more preferably a salt with hydrohalic acid. Or a salt with hydrochloric acid.
- aqueous sodium hydroxide solution 9.6 g, 12 mmo 1
- t-butinolemenolecaptan 1.13 mL, 1 Ommo 1
- Acetone (0.79 mL, 1 Ommo 1) was added, and the mixture was heated to room temperature and reacted for 2 hours.
- the reaction solution was pale yellow and separated into two phases.
- a Dimroth condenser tube reactor Na CN (588mg, 1 2mmo 1), the (NH 4) HC0 3 (2. 77 g, 3 5 mm o 1), 28% en Monia water (3.
- Bacillus sp. KN 245 strain (FERM BP-4863) was cultured, collected, and then subjected to ultrasonic crushing to obtain an enzyme solution.
- the obtained optically active 5-t-butylthiomethyl-5-methylhydantoin was confirmed to be D-form by HP LC analysis with a separately synthesized sample (column: CHI RALPAK AD (manufactured by Daicel)).
- Mobile phase: Hexanoisopropanol 10/1, Flow rate: 1 ml / min, Detection wavelength: 210 nm, Column temperature: 30. C, D form: 14.7 minutes, L form: 25.3 minutes) This was confirmed by comparing the retention times.
- Example 2 Method for producing N-potassium Sb-t-butyl-l-methyl-L-cysteine using transformed microorganism Escherichia coli HB101 PTH104
- Bacillus sp. Strain KNK245 (FERM BP-4863) was transformed with Escherichia coli HB101 pTH104 (FE RM B P-4864) incorporating the hydantoinase gene into a 10 ml liquid medium (10 g / 1 tripton). , LOg / 1 yeast extract, 5 g / l NaCl, pH7, sterilized at 120 ° C for 15 minutes, and then added lOOmg / 1 ampicillin by filtration sterilization) and inoculated at 37 ° C. For 18 hours with shaking.
- This culture solution (lml) was sterilized in a 500 ml Sakaguchi flask at 120 ° C for 15 minutes in a 50 ml liquid medium (10 gZ1 tryptone, lOg / 1 yeast extract, 5 g / 1 NaC1, H The cells were inoculated into 7) and cultured with shaking at 37 ° C for 24 hours. The cells obtained by centrifugation from 1 ml of this culture were suspended in 1.5 ml of 0.1 M potassium phosphate buffer (pH 7.0), and the racemic N-potassium was used as a suspension.
- 0.1 M potassium phosphate buffer pH 7.0
- Example 1 From the comparison of the retention time with ⁇ -methyl-L-cystine, it was confirmed to be the L-isomer.
- Example 3 A method for producing L-baumyl-S-t-butyl-a-methyl-L-cysteine using Bacillus bacteria
- Bacteria sp. KNK245 strain (FERM BP-4863) was sterilized in a 500-ml 1-volume flask at 120 ° C for 15 minutes. / 1 polypeptone, l O GZL meat extract, 5 g / l Isu Toekisu was inoculated into P H7. 5), and cultured with shaking 1 5 h at 4 5 ° C. 2 ml of this culture solution was inoculated into a medium obtained by adding 1 gZl perilacil and 20 mg / l manganese chloride to the above medium components, and cultured at 45 ° C for 24 hours with shaking.
- the cells obtained by centrifugation from 15 ml of this culture solution were suspended in 1.5 ml of 0.1 M potassium phosphate buffer ( ⁇ 7.0), and the racemic ⁇ -force rubamoyl-St was suspended.
- 0.1 M potassium phosphate buffer ⁇ 7.0
- the racemic ⁇ -force rubamoyl-St was suspended.
- Butinole ⁇ -methinoresistin 15 Orag and 0.5 M manganese sulfate aqueous solution (0.003 ml) were added, and the pH was adjusted to 6.5 with 1 ON aqueous sodium hydroxide solution. Then, while maintaining the pH at around 6.5 with 6N hydrochloric acid, the mixture was stirred and reacted at 40 ° C. for 19 hours.
- Example 4 The N-force obtained in Example 1 was compared with the N-force rubamoyl-S-t-butyl- ⁇ -methyl-L-cysteine to confirm that it was a lactate. (Example 4) Method for producing N-potassium rubamoyl-St-butyl- ⁇ -methyl-L-cysteine using Pseudomonas sp.
- One platinum loop of this cell was sterilized in a 50-Om 1-volume flask at 120 ° C for 15 minutes in a 10-Om 1 liquid medium (20 g / 1 meat extract, 6 g / 1 glycerol, lgZl peracil, 2 g / l Potassium dihydrogen phosphate, lg / 1 Magnesium sulfate heptahydrate, 40 mg Zl Calcium chloride dihydrate, 20 mg Z 1 Ferrous sulfate heptahydrate, 20 mg / 1 Manganese sulfate tetra-hexahydrate , 2 Omg / 1 copper sulfate pentahydrate, pH 5.5), and cultured with shaking at 30 for 24 hours.
- a 10-Om 1 liquid medium (20 g / 1 meat extract, 6 g / 1 glycerol, lgZl peracil, 2 g / l Potassium dihydrogen phosphate, lg / 1 Magn
- the cells obtained by centrifugation from 10 ml of this culture were suspended in 1 ml of 0.1 M potassium phosphate buffer (pH 7.0), and the racemic N-potassium S-t-butyl-methyl 1 Omg of noresistin and 0.002 ml of a 0.5 M manganese sulfate aqueous solution were added. Then, the reaction was carried out by stirring at 40 ° C. for 50 hours while maintaining the pH at around 6.5 with 6N hydrochloric acid.
- the residual ratio of N-butyrubamoyl-S_t-butyl- ⁇ -methylcysteine was 52%.
- Agrobacterium 'species KNK 712 strain (FERM BP-1900) was sterilized in a large test tube at 120 ° C for 15 minutes in a 10 ml liquid medium (10 g / 1 polypeptone, lOg / 1 Inoculate meat extract, 5 g / l yeast extract, 5 g / 1 glycerin, 5 gZl potassium dihydrogen phosphate, 5 gZl disodium hydrogen phosphate, ⁇ 6.5) and shake at 30 ° C for 24 hours. Culture was continued.
- This culture solution (lml) was added to 10 Om1 liquid medium (25 g / 1 glycerin, 5 g / 1 sucrose, 5 g Zi potassium dihydrogen phosphate, 5 g / l sodium dihydrogen phosphate, lg / 1 phosphorus Magnesium heptahydrate, l OmgZl Manganese chloride tetrahydrate, 4 g / l yeast extract, pH 6.5, sterilized at 120 ° C for 15 minutes, 2 g / 1 l rare, lg / 1 D—N ⁇ - ⁇ - ⁇ - ⁇ - ⁇ -hydroxyphenyldaricin was added by filtration sterilization), and cultured with shaking at 33 ° C for 23 hours.
- Om1 liquid medium 25 g / 1 glycerin, 5 g / 1 sucrose, 5 g Zi potassium dihydrogen phosphate, 5 g / l sodium dihydrogen phosphate, lg / 1 phosphorus Magnesium
- the cells obtained by centrifugation from 5 ml of this culture were suspended in lm 1 of 0.1 M potassium phosphate buffer (pH 7.0), and racemic N-carpamoyl-S-t-butyl- ⁇ -methyl 1 Omg of cysteine and 0,002 ml of 0.5 M manganese sulfate aqueous solution were added. Then, the reaction was carried out by stirring at 40 ° C. for 5 hours while maintaining 61 ⁇ hydrochloric acid 1) «[around 6.5.
- Examplementation_Example 6 Preparation of D-5-t-butylthiomethyl-5-methylhydantoin Removal of S-t-butyl- ⁇ -methyl-L-cysteine contained as an impurity in a mixture (50 g) of the enzyme obtained by the method of Example 3 and D-5-t-butylthiomethyl-5-methylhydantoin To this end, water (400 g) was added and the mixture was stirred, and then insolubles were collected by filtration and further washed with water (200 g). To this was added a 5 wt% aqueous sodium hydroxide solution (120 g), and the mixture was stirred.
- ⁇ -Canolebamoinole-S-t-butinole ⁇ -methinole-L-cysteine (100 mg, 0.43 mmo 1) is dissolved in concentrated hydrochloric acid (lmL), refluxed under nitrogen for 60 hours, and ⁇ -methyl-L-cysteine hydrochloric acid is dissolved. An aqueous solution of the salt was obtained.
- Example 9 To the ⁇ -methyl-L-cysteine hydrochloride reaction solution obtained in Example 9, isopropyl alcohol (0.5 mL) was added, and the mixture was concentrated under reduced pressure to perform azeotropic dehydration. The same operation was repeated three times, and when the volume became about 1/3, concentration was stopped. Heating, toluene (1 mL) was added, and the mixture was allowed to cool to room temperature with stirring. After stirring for about 1 hour as it was, the precipitated crystals were collected by filtration, washed with toluene, and dried under reduced pressure to give the title compound as a white solid (44.3 mg). Analysis by HPLC (under the analysis conditions of Example 8) confirmed that the product was the target compound (yield: 60.0%).
- N-Canolebamoinole S_t-butyl-a-methinole L-cysteine 82.4 g, 351.4 mmol was dissolved in 18% aqueous lithium hydroxide (630 g) and refluxed under nitrogen for 41 hours. After allowing to cool to room temperature, concentrated solution (180.1 g) was added to the solution after filtering off the insoluble matter, the pH was adjusted to 6, the mixture was stirred for about 1 hour, and then cooled to 4-5 ° C. The mixture was further stirred for 1 hour. The obtained crystals were collected by filtration, washed with water, and dried under reduced pressure to give the title compound as a white solid (53.9 g).
- the ⁇ -methyl-L-cysteine hydrochloride reaction solution obtained in Example 12 was concentrated to 67.5 g (pressure reduction: 30 to 6 OmmHg, temperature: 45 ° C), toluene (206 g) was added, and the pressure was reduced. A concentration operation (pressure reduction 40 to 6 OmmHg, temperature 40 ° C, distilling speed 107 L / h ⁇ m 2 ) was performed to a total amount of 109 g. Further, toluene (206 g) was added and the mixture was concentrated, and the same operation was repeated a total of 6 times to obtain the obtained ⁇ -methyl-L monocysteine hydrochloride toluene slurry (104 g).
- Example 15 Method for producing D-5-mercaptomethyl-5-methylhydantoin D-5-t-butylthiomethyl-15-methylhydantoin (4.38 g) obtained in Example 6 was concentrated hydrochloric acid (100%). g) and stirred at 80 ° C for 18.5 hours. After allowing it to cool to room temperature, concentrate it to about half the volume, then add 30 wt% sodium hydroxide The pH was adjusted to 0 by adding 30.5 g of an aqueous solution of platinum. After extraction with ethyl acetate (10 OmLX 3), the organic phase was concentrated to 10% of the total volume, and toluene (30 mL) was added.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002486350A CA2486350A1 (en) | 2002-06-05 | 2003-06-05 | Process for producing optically active .alpha.-methylcysteine derivative |
AU2003242072A AU2003242072A1 (en) | 2002-06-05 | 2003-06-05 | PROCESS FOR PRODUCING OPTICALLY ACTIVE Alpha-METHYLCYSTEINE DERIVATIVE |
EP20030730820 EP1550725A4 (en) | 2002-06-05 | 2003-06-05 | PROCESS FOR PRODUCING OPTICALLY ACTIVE alpha-METHYLCYSTEINE DERIVATIVE |
US10/515,658 US20060105435A1 (en) | 2002-06-05 | 2003-06-05 | Process for producing optically active alpha-methylcysteine derivative |
KR10-2004-7018717A KR20050010826A (ko) | 2002-06-05 | 2003-06-05 | 광학 활성 α-메틸시스테인 유도체의 제조 방법 |
JP2004513502A JP4485941B2 (ja) | 2002-06-05 | 2003-06-05 | 光学活性α−メチルシステイン誘導体の製造方法 |
US12/757,947 US20100197934A1 (en) | 2002-06-05 | 2010-04-09 | Process for producing optically active alpha-methylcysteine derivative |
US13/897,079 US8993800B2 (en) | 2002-06-05 | 2013-05-17 | Process for producing optically active α-methylcysteine derivative |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002-164598 | 2002-06-05 | ||
JP2002164598 | 2002-06-05 | ||
JP2002237698 | 2002-08-16 | ||
JP2002-237698 | 2002-08-16 | ||
JP2003-67299 | 2003-03-12 | ||
JP2003067299 | 2003-03-12 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/515,658 A-371-Of-International US20060105435A1 (en) | 2002-06-05 | 2003-06-05 | Process for producing optically active alpha-methylcysteine derivative |
US12/757,947 Division US20100197934A1 (en) | 2002-06-05 | 2010-04-09 | Process for producing optically active alpha-methylcysteine derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003106689A1 true WO2003106689A1 (ja) | 2003-12-24 |
Family
ID=29740538
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/007108 WO2003106689A1 (ja) | 2002-06-05 | 2003-06-05 | 光学活性α−メチルシステイン誘導体の製造方法 |
Country Status (7)
Country | Link |
---|---|
US (3) | US20060105435A1 (ja) |
EP (2) | EP2287152B1 (ja) |
JP (2) | JP4485941B2 (ja) |
KR (1) | KR20050010826A (ja) |
AU (1) | AU2003242072A1 (ja) |
CA (1) | CA2486350A1 (ja) |
WO (1) | WO2003106689A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004063385A1 (ja) * | 2003-01-10 | 2004-07-29 | Kaneka Corporation | 光学活性α−メチルシステイン誘導体の製造方法 |
WO2005123932A3 (en) * | 2004-06-15 | 2006-04-27 | Avecia Pharmaceuticals Ltd | Process for the preparation of optically active alpha-substituted carboxylic acids or alpha-substituted carboxylic acid amides from enantiomeric mixtures of alpha-substituted carboxylic acid amides employing pseudomonas fluorescens |
WO2006103995A1 (ja) * | 2005-03-25 | 2006-10-05 | Kaneka Corporation | 光学活性α-アミノ酸誘導体の製造方法 |
US10071958B2 (en) | 2013-05-02 | 2018-09-11 | Api Corporation | Method for producing alpha-substituted cysteine or salt thereof or synthetic intermediate of alpha-substituted cysteine |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
SE0202539D0 (sv) | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
SE0401762D0 (sv) | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
US7648992B2 (en) | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
SE0403085D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
SE0403086D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
TW200800954A (en) * | 2006-03-16 | 2008-01-01 | Astrazeneca Ab | Novel crystal modifications |
TW200831488A (en) | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4948534B1 (ja) * | 1970-09-29 | 1974-12-21 | ||
JPS5658493A (en) * | 1979-10-16 | 1981-05-21 | Kanegafuchi Chem Ind Co Ltd | Preparation of n-carbamoyl-d-alpha-amino acids |
EP0175312A2 (en) * | 1984-09-17 | 1986-03-26 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Process for preparing optically active hydantoins |
US5338859A (en) * | 1993-02-12 | 1994-08-16 | Hoechst Celanese Corporation | Process for the production of calcium salts of hydantoic acids |
EP0725142A1 (en) * | 1994-06-24 | 1996-08-07 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Process for producing d-amino acid by using composite immobilized enzyme preparation |
EP0801131A1 (en) * | 1994-12-28 | 1997-10-15 | Kanegafuchi Chemical Industry Co., Ltd. | PROCESS FOR PRODUCING D-N-CARBAMOYL-$g(a)-AMINO ACID |
WO2001072702A2 (en) * | 2000-03-24 | 2001-10-04 | Pharmacia Corporation | Amidino compounds useful as nitric oxide synthase inhibitors |
WO2002074750A1 (en) * | 2001-03-15 | 2002-09-26 | Astrazeneca Ab | Metalloproteinase inhibitors |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3849574A (en) * | 1971-05-24 | 1974-11-19 | Colgate Palmolive Co | Alpha-substituted-beta-arylthioalkyl amino-acids,for increasing heart rate |
JPS582227B2 (ja) | 1974-02-04 | 1983-01-14 | 住友化学工業株式会社 | アルフア− − アミノサン ノ セイゾウホウホウ |
JPH0623148B2 (ja) | 1985-09-05 | 1994-03-30 | 三井東圧化学株式会社 | N−アセチル−dl−アミノ酸の製造方法 |
JPH01124398A (ja) | 1988-09-14 | 1989-05-17 | Kanegafuchi Chem Ind Co Ltd | 光学活性ヒダントイン類の製造方法 |
JPH0395145A (ja) | 1989-09-08 | 1991-04-19 | Sumitomo Chem Co Ltd | α―アミノ酸の製造方法 |
JPH07222593A (ja) | 1994-02-08 | 1995-08-22 | Ajinomoto Co Inc | N−カルバミル−L−tert−ロイシンの製造方法 |
JP3630785B2 (ja) | 1995-08-08 | 2005-03-23 | 三洋電機株式会社 | 紙幣搬送装置 |
DE19529211C2 (de) * | 1995-08-09 | 1999-01-14 | Degussa | Verfahren zur Herstellung von (R)-tertiär-Leucin |
HRP980093A2 (en) | 1997-02-28 | 1998-12-31 | Lilly Co Eli | Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting "beta"-amyloid peptide release and/or its synthesis by use of such compounds |
US6407281B1 (en) * | 1998-01-13 | 2002-06-18 | Kaneka Corporation | Process for producing optically active cysteine derivatives |
JPH11243989A (ja) | 1998-03-04 | 1999-09-14 | Tanabe Seiyaku Co Ltd | 光学活性環状ビアリール化合物の製法 |
FR2788271B1 (fr) * | 1999-01-07 | 2001-02-09 | Rhone Poulenc Agrochimie | Nouveau procede de preparation d'aminoacides chiraux |
DE19942812A1 (de) | 1999-09-08 | 2001-03-15 | Degussa | Verfahren zur Herstellung von D-(3'-Pyridyl)-alanin |
-
2003
- 2003-06-05 CA CA002486350A patent/CA2486350A1/en not_active Abandoned
- 2003-06-05 JP JP2004513502A patent/JP4485941B2/ja not_active Expired - Lifetime
- 2003-06-05 AU AU2003242072A patent/AU2003242072A1/en not_active Abandoned
- 2003-06-05 EP EP10193643.3A patent/EP2287152B1/en not_active Expired - Lifetime
- 2003-06-05 KR KR10-2004-7018717A patent/KR20050010826A/ko not_active Abandoned
- 2003-06-05 WO PCT/JP2003/007108 patent/WO2003106689A1/ja active Application Filing
- 2003-06-05 EP EP20030730820 patent/EP1550725A4/en not_active Withdrawn
- 2003-06-05 US US10/515,658 patent/US20060105435A1/en not_active Abandoned
-
2009
- 2009-09-18 JP JP2009217497A patent/JP5096435B2/ja not_active Expired - Fee Related
-
2010
- 2010-04-09 US US12/757,947 patent/US20100197934A1/en not_active Abandoned
-
2013
- 2013-05-17 US US13/897,079 patent/US8993800B2/en not_active Expired - Fee Related
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4948534B1 (ja) * | 1970-09-29 | 1974-12-21 | ||
JPS5658493A (en) * | 1979-10-16 | 1981-05-21 | Kanegafuchi Chem Ind Co Ltd | Preparation of n-carbamoyl-d-alpha-amino acids |
EP0175312A2 (en) * | 1984-09-17 | 1986-03-26 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Process for preparing optically active hydantoins |
US5338859A (en) * | 1993-02-12 | 1994-08-16 | Hoechst Celanese Corporation | Process for the production of calcium salts of hydantoic acids |
EP0725142A1 (en) * | 1994-06-24 | 1996-08-07 | Kanegafuchi Kagaku Kogyo Kabushiki Kaisha | Process for producing d-amino acid by using composite immobilized enzyme preparation |
EP0801131A1 (en) * | 1994-12-28 | 1997-10-15 | Kanegafuchi Chemical Industry Co., Ltd. | PROCESS FOR PRODUCING D-N-CARBAMOYL-$g(a)-AMINO ACID |
WO2001072702A2 (en) * | 2000-03-24 | 2001-10-04 | Pharmacia Corporation | Amidino compounds useful as nitric oxide synthase inhibitors |
WO2002074750A1 (en) * | 2001-03-15 | 2002-09-26 | Astrazeneca Ab | Metalloproteinase inhibitors |
Non-Patent Citations (3)
Title |
---|
MULQUEEN G.C. ET AL.: "Synthesis of the thiazoline-based siderophore (S)-desferrithiocin", TETRAHEDRON, vol. 49, no. 24, 1993, pages 5359 - 5364, XP001119496 * |
PATTENDEN G. ET AL.: "Enantioselective synthesis of 2-alkyl substituted cysteines", TETRAHEDRON, vol. 49, no. 10, 1993, pages 2131 - 2138, XP002174899 * |
See also references of EP1550725A4 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004063385A1 (ja) * | 2003-01-10 | 2004-07-29 | Kaneka Corporation | 光学活性α−メチルシステイン誘導体の製造方法 |
WO2005123932A3 (en) * | 2004-06-15 | 2006-04-27 | Avecia Pharmaceuticals Ltd | Process for the preparation of optically active alpha-substituted carboxylic acids or alpha-substituted carboxylic acid amides from enantiomeric mixtures of alpha-substituted carboxylic acid amides employing pseudomonas fluorescens |
WO2006103995A1 (ja) * | 2005-03-25 | 2006-10-05 | Kaneka Corporation | 光学活性α-アミノ酸誘導体の製造方法 |
US10071958B2 (en) | 2013-05-02 | 2018-09-11 | Api Corporation | Method for producing alpha-substituted cysteine or salt thereof or synthetic intermediate of alpha-substituted cysteine |
Also Published As
Publication number | Publication date |
---|---|
CA2486350A1 (en) | 2003-12-24 |
KR20050010826A (ko) | 2005-01-28 |
US20130261331A1 (en) | 2013-10-03 |
JP5096435B2 (ja) | 2012-12-12 |
JP2009292842A (ja) | 2009-12-17 |
JPWO2003106689A1 (ja) | 2005-10-13 |
US20100197934A1 (en) | 2010-08-05 |
EP2287152A3 (en) | 2011-03-09 |
EP1550725A1 (en) | 2005-07-06 |
US8993800B2 (en) | 2015-03-31 |
EP1550725A4 (en) | 2010-08-25 |
JP4485941B2 (ja) | 2010-06-23 |
US20060105435A1 (en) | 2006-05-18 |
EP2287152A2 (en) | 2011-02-23 |
EP2287152B1 (en) | 2015-01-14 |
AU2003242072A1 (en) | 2003-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5096435B2 (ja) | 光学活性α−メチルシステイン誘導体の製造方法 | |
JPWO2004022766A1 (ja) | L−α−メチルシステイン誘導体の製造方法 | |
WO2008047656A1 (fr) | Procédé de fabrication d'un acide l-amino | |
JPWO2011078172A1 (ja) | 光学活性3−置換グルタル酸モノアミドの製造法 | |
US6987010B2 (en) | Process for the enzymatic preparation of enantiomer-enriched β-amino acids | |
KR101043190B1 (ko) | 거울상이성체가 풍부한 β-아미노산의 효소에 의한 제조방법 | |
JP4735263B2 (ja) | 光学活性2−アルキルシステインの製造方法、並びにその誘導体及び製造方法 | |
CN1928102B (zh) | 一种拆分β-氨基酸的方法 | |
Ohishi et al. | Enantioselective synthesis of D-and L-α-methylcysteine with hydantoinase | |
US5120855A (en) | Formation of hydroxyaromatic ketoacetal from a hydroxyaromatic methylketone and production of 5-(4'-hydroxyphenyl)hydantoin and Dp-hydroxyphenylglycine from 4-hydroxyacetophenone | |
WO2004007741A1 (ja) | 光学活性β−アミノニトリル化合物及びその対掌体アミド化合物の製造方法 | |
WO2004063385A1 (ja) | 光学活性α−メチルシステイン誘導体の製造方法 | |
JP2009278914A (ja) | 光学活性芳香族アミノ酸および光学活性芳香族アミノ酸アミドの製造方法 | |
JP2002306194A (ja) | 光学活性シアンヒドリンの製造方法 | |
WO2014157651A1 (ja) | アミノ酸アミド化合物及びアミノ酸の製造方法、並びにイミダゾリジン化合物 | |
IE910438A1 (en) | FORMATION OF HYDROXYAROMATIC KETOACETAL FROM AN¹HYDROXYAROMATIC METHYLKETONE AND PRODUCTION OF¹5-(4'-HYDROXYPHENYL) HYDANTOIN AND D-p-HYDROXYPHENYLGLYCINE¹FROM 4-HYDROXYACETOPHENONE | |
JP2003277343A (ja) | 新規N−カルバモイル−α−アミノ酸及びその製造方法 | |
JP2007074942A (ja) | 光学活性ペニシラミンの製造方法 | |
WO2007023948A1 (ja) | 光学活性(S又はR)-α-アミノ酸及び光学活性(R又はS)-α-アミノ酸エステルの製造方法 | |
JP2012193135A (ja) | アミノ酸の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004513502 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2486350 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047018717 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003730820 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020047018717 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2003730820 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006105435 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10515658 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10515658 Country of ref document: US |